Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Last Updated: June 3, 2023

CLINICAL TRIALS PROFILE FOR IMIPENEM AND CILASTATIN

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

All Clinical Trials for Imipenem And Cilastatin

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00080496 ↗	Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	2003-07-01	To compare the efficacy and safety of the tigecycline regimen with that of the imipenem/cilastatin regimen in subjects with nosocomial pneumonia.
NCT00081744 ↗	Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	2002-11-01	Purpose: To provide a mechanism for the emergency use of tigecycline in the appropriate clinical situations.
NCT00136201 ↗	Study Comparing Tigecycline and Imipenem/Cilastatin in Chinese Subjects With Complicated Intra-Abdominal Infections	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	2005-11-01	The primary objective of this study is to compare the safety and efficacy of an experimental antibiotic to a marketed antibiotic in the treatment of Chinese subjects with complicated intra-abdominal infections.
NCT00236834 ↗	A Study of the Safety and Effectiveness of Levofloxacin Compared With Imipenem/Cilastatin in Patients With Pneumonia Acquired During Hospitalization	Completed	PriCara, Unit of Ortho-McNeil, Inc.	Phase 3	1997-12-01	The purpose of this study is to compare the safety and effectiveness of levofloxacin with imipenem/cilastatin in the treatment of hospital-acquired pneumonia
NCT00236834 ↗	A Study of the Safety and Effectiveness of Levofloxacin Compared With Imipenem/Cilastatin in Patients With Pneumonia Acquired During Hospitalization	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 3	1997-12-01	The purpose of this study is to compare the safety and effectiveness of levofloxacin with imipenem/cilastatin in the treatment of hospital-acquired pneumonia
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Imipenem And Cilastatin

Condition Name

Chart
Table

Condition Name for Imipenem And Cilastatin
Intervention	Trials
Bacterial Infections	7
Pneumonia, Bacterial	3
Urinary Tract Infections	3
Bacterial Pneumonia	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Imipenem And Cilastatin
Intervention	Trials
Infections	21
Infection	19
Communicable Diseases	16
Bacterial Infections	11
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Imipenem And Cilastatin

Trials by Country

Map
Table

Trials by Country for Imipenem And Cilastatin
Location	Trials
United States	74
China	41
Japan	21
Ukraine	18
Russian Federation	12
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Imipenem And Cilastatin
Location	Trials
California	6
Texas	5
Florida	4
Ohio	4
North Carolina	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Imipenem And Cilastatin

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Imipenem And Cilastatin
Clinical Trial Phase	Trials
Phase 4	7
Phase 3	14
Phase 2/Phase 3	1
[disabled in preview]	9
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Imipenem And Cilastatin
Clinical Trial Phase	Trials
Completed	19
Recruiting	7
Unknown status	6
[disabled in preview]	8
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Imipenem And Cilastatin

Sponsor Name

Chart
Table

Sponsor Name for Imipenem And Cilastatin
Sponsor	Trials
Merck Sharp & Dohme Corp.	13
Sinovent Pty Ltd.	6
Wyeth is now a wholly owned subsidiary of Pfizer	3
[disabled in preview]	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Imipenem And Cilastatin
Sponsor	Trials
Industry	37
Other	22
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey

Johnson and Johnson

Express Scripts

Medtronic

AstraZeneca

Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.